Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | PTGES | O14684 | 4/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189346 | 0.91 | LMNA (0.85) | LMNAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL2186013 | 0.89 | ALDH1A1 (0.77) | LMNAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3379849 | 0.89 | MAPT (0.59) | LMNAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3379944 | 0.85 | MAPT (0.55) | LMNAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3376926 | 0.85 | MAPT (0.60) | LMNAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL2188004 | 0.84 | ALDH1A1 (0.65) | LMNAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL10250146 | 0.83 | LMNA (1.00) | LMNAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL13064484 | 0.83 | MEN1 (0.78) | LMNAALDH1A1MEN1KMT2ATAS2R14 | |
| SCHEMBL302059 | 0.82 | LMNA (0.52) | LMNAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL30076627 | 0.82 | MCL1 (0.67) | KMT2AMAPTTAS2R14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342177-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-9447033-B2 | Potassium channel blockers | JAPAN TOBACCO INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20150259282-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-9073834-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2015-07-07 | — | — | US | disclosed |
| US-20140221337-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2014-08-07 | — | — | US | disclosed |
| US-8673901-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2014-03-18 | — | — | US | disclosed |
| EP-2342177-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | Xention Limited (GB) | 2011-07-13 | — | — | EP | disclosed |
| US-20100087428-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| WO-2010023448-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221337-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | LMNA 1619/4885ALDH1A1 1360/4885MEN1 608/4885 |
| US-20100087428-A1 | Novel Potassium Channel Blockers | HCN4, SCN2B, KCNH2 | LMNA 2145/4885ALDH1A1 3795/4885MEN1 2747/4885 |
| US-20150259282-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | LMNA 1619/4885ALDH1A1 1360/4885MEN1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.